Thomas Makris
Overview
Explore the profile of Thomas Makris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Thomopoulos C, Katsimagklis G, Makris T
J Clin Hypertens (Greenwich)
. 2018 Jan;
20(1):45-46.
PMID: 29338106
No abstract available.
12.
Katsi V, Georgountzos G, Kallistratos M, Zerdes I, Makris T, Manolis A, et al.
Front Pharmacol
. 2017 May;
8:247.
PMID: 28529486
Preeclampsia has been linked to high morbidity and mortality during pregnancy. However, no efficient pharmacological options for the prevention of this condition are currently available. Preeclampsia is thought to share...
13.
Katsi V, Georgiopoulos G, Marketou M, Oikonomou D, Parthenakis F, Makris T, et al.
Curr Med Res Opin
. 2017 May;
33(8):1497-1504.
PMID: 28498066
Background: Atrial fibrillation (AF) constitutes a relatively infrequent pregnancy complication, which may be a therapeutic Gordian knot. Indeed, sparse data exist regarding the prevalence, prognosis, and management of AF during...
14.
Thomopoulos C, Katsimagklis G, Archontakis S, Skalis G, Makris T
Curr Vasc Pharmacol
. 2017 Apr;
16(1):61-65.
PMID: 28413969
Fixed-dose triple drug combinations represent one of the latest innovations of pharmacotherapy for hypertension (HT). They combine a traditional renin-angiotensin system blocker, a diuretic and a calcium channel blocker. The...
15.
Thomopoulos C, Katsimagklis G, Makris T
J Hypertens
. 2016 Dec;
35(1):27-28.
PMID: 27902624
No abstract available.
16.
Katsi V, Skalis G, Pavlidis A, Makris T, Nihoyannopoulos P, Tousoulis D, et al.
Eur Heart J Cardiovasc Pharmacother
. 2016 Aug;
1(4):260-4.
PMID: 27532450
The need for novel antihypertensive therapies represents a continuous challenge. LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor that has been shown to enhance endogenous natriuretic peptide (NP) actions on...
17.
Katsi V, Kanellopoulou T, Makris T, Nihoyannopoulos P, Nomikou E, Tousoulis D
Curr Hypertens Rep
. 2016 Jun;
18(7):57.
PMID: 27251704
Preeclampsia is a hypertensive disorder of pregnancy that remains a significant cause of maternal morbidity and mortality worldwide. Preeclampsia can be resolved by delivery, and most of the proposed preventive...
18.
Thomopoulos C, Skalis G, Michalopoulou H, Tsioufis C, Makris T
Clin Cardiol
. 2015 Aug;
38(12):763-9.
PMID: 26282344
This analysis investigated the extent of different outcome reductions from low-density lipoprotein cholesterol (LDL-C) lowering following ezetimibe/simvastatin treatment and the proportionality of outcome to LDL-C reductions. The authors searched PubMed...
19.
Katsi V, Zerdes I, Manolakou S, Makris T, Nihoyannopoulos P, Tousoulis D, et al.
Recent Adv Cardiovasc Drug Discov
. 2015 Jul;
9(2):63-72.
PMID: 26123049
The introduction of therapies that inhibit tumor angiogenesis and particularly target to vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) (VEGF inhibitors/VEGFi) have revolutionized the treatment...
20.
Thomopoulos C, Skalis G, Makris T
J Clin Hypertens (Greenwich)
. 2015 Apr;
17(8):578-9.
PMID: 25891442
No abstract available.